Latest News

Latest News

News from the World Hepatitis Alliance

How will 2015 be a defining year for the Alliance?

28 Feb 2015 Bridie Taylor

Viral hepatitis is a global killer with alarming mortality rates, yet an increased global commitment to tackling the disease and ground-breaking new...

How does the Alliance really represent hepatitis patients?

28 Feb 2015 Bridie Taylor

The World Hepatitis Alliance prides itself as the true voice of hepatitis patients living all over the world. All our work is overseen by an...

WHA in official relations with WHO: What does this mean for you?

28 Feb 2015 Bridie Taylor

Fundamental to our ability to influence global hepatitis policy and bring about real change in the world of hepatitis is our relationship with the...

Need some inspiration for action? : Initiatives from WHA members

28 Feb 2015 Bridie Taylor

Together our voices are stronger and united we can tackle this global killer! The World Hepatitis Alliance is fortunate enough to be made up of...

What is the future for hepatitis treatments? And how we can fund hepatitis programmes?

28 Feb 2015 Bridie Taylor

Discussions around hepatitis are dominated by the pioneering new treatments rapidly transforming the landscape and the ensuing heated discussions...

Assisting WHO in the development of a global strategy

31 Jan 2015 Bridie Taylor

World Health Organization Member States have urged WHO to develop a comprehensive global strategy on hepatitis. To assist in the development of this...

World Hepatitis Alliance’s ever-growing membership base

31 Jan 2015 Bridie Taylor

Central to the success of the World Hepatitis Alliance are our member groups around the world. To stimulate political interest in and action on...

Joining expert committees to promote harm reduction

31 Jan 2015 Bridie Taylor

Harm reduction policies are proven to save lives. Globally, as many as 67% of People Who Inject Drugs (PWIDs) have hepatitis C and an additional 8.4...

Promoting screening among high risk communities with new multi-lingual tool

31 Jan 2015 Bridie Taylor

In Europe, migrant populations are disproportionally affected by hepatitis B and C. Crucial to reducing the burden is improving screening among these...

Supporting the development of national action plans in South America

31 Jan 2015 Bridie Taylor

Government commitment to comprehensive national action plans is key to addressing the burden of viral hepatitis. To support the development of...

Exploring new treatment developments and innovative ways to finance healthcare

31 Jan 2015 Bridie Taylor

New therapeutic developments are revolutionising the way hepatitis is treated. But with a global lack of funding, how can these pioneering new drugs...

Pages

News from infohep

DAA treatment reduces the risk of death and liver cancer in France

12 Feb 2019 Keith Alcorn
Treatment with direct-acting antivirals (DAAs) reduced the risk of death, liver cancer and death from liver-related causes in French people with...

Tackling HIV and hepatitis C in Europe: towards minimum standards

11 Feb 2019 Gus Cairns
Despite the huge disparities in care that were highlighted, last week's Standard of Care for HIV and Coinfections in Europe meeting in...

Hepatitis C cure does not improve glucose control in type 2 diabetes

7 Feb 2019 Michael Carter
A successful response to hepatitis C virus (HCV) therapy does not result in long-term improvements in glucose metabolism for people with type 2...

Immunotherapy combinations show promise for liver cancer

4 Feb 2019 Liz Highleyman
Checkpoint inhibitor immunotherapy combinations may slow disease progression in people with hepatocellular carcinoma (HCC), according to two small...

Generic DAAs achieve excellent cure rates in Egypt matching those of branded drugs at a fraction of the cost

1 Feb 2019 Michael Carter
Generic direct-acting antivirals (DAAs) are just as effective and safe as their branded equivalents for the treatment of chronic hepatitis C virus (...

Experimental therapy improves liver health in people with fatty liver disease

31 Jan 2019 Liz Highleyman
NGM282, an experimental fibroblast growth factor analogue, reduced liver fat build-up and the development of scar tissue in people with non-alcoholic...

WHO hepatitis C elimination targets are achievable, model shows – if 51 million treated by 2030

29 Jan 2019 Keith Alcorn
Expanding hepatitis C screening to diagnose 90% of people by 2030, providing treatment to everyone with hepatitis C, scaling up harm reduction and...

HIV infection an independent risk factor for poorer survival from liver cancer

28 Jan 2019 Michael Carter
Infection with HIV is associated with significantly worse survival for people with hepatocellular carcinoma (HCC, the most common type of...

Conditional cash transfers may improve HCV screening and treatment in drug users

22 Jan 2019 Keith Alcorn
Conditional cash transfers – giving money to encourage use of services – may be needed to reach drug users for hepatitis C testing and treatment if...

Barriers to HCV treatment access from the drug user's point of view: stigma, complex lives and damaged veins

16 Jan 2019 Keith Alcorn
Despite access to hepatitis C treatment, many people who inject drugs still perceive numerous barriers to starting treatment, including the...